Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an In Vitro Evaluation von RIZK, Matthew L, HOULE, Robert, GRACE HOYEE CHAN, HAFEY, Mike, RHEE, Elizabeth G, XIAOYAN CHU

Volltext

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors von Tucker, Thomas J, Embrey, Mark W, Alleyne, Candice, Amin, Rupesh P, Bass, Alan, Bhatt, Bhavana, Bianchi, Elisabetta, Branca, Danila, Bueters, Tjerk, Buist, Nicole, Ha, Sookhee N, Hafey, Mike, He, Huaibing, Higgins, John, Johns, Douglas G, Kerekes, Angela D, Koeplinger, Kenneth A, Kuethe, Jeffrey T, Li, Nianyu, Murphy, BethAnn, Orth, Peter, Salowe, Scott, Shahripour, Aurash, Tracy, Rodger, Wang, Weixun, Wu, Chengwei, Xiong, Yusheng, Zokian, Hratch J, Wood, Harold B, Walji, Abbas

Volltext

Madin-Darby Canine Kidney II Cells: A Pharmacologically Validated System for NPC1L1-Mediated Cholesterol Uptake von Weinglass, Adam B., Köhler, Martin G., Nketiah, Emmanuel O., Liu, Jessica, Schmalhofer, William, Thomas, Anu, Williams, Brande, Beers, Lindsey, Smith, Lauren, Hafey, Mike, Bleasby, Kelly, Leone, Joseph, Tang, Yui Sing, Braun, Matthew, Ujjainwalla, Feroze, McCann, Margaret E., Kaczorowski, Gregory J., Garcia, Maria L.

Volltext